Phathom Pharmaceuticals, Inc. (PHAT) Cash Flow Statement

The OCF-to-net-income ratios above 0.7 across most periods indicate that the reported losses were predominantly real cash losses instead of non-cash charges, which is the more concerning pattern for an investor. The 2026Q3 quarter produced positive operating cash flow of $1.8M against a net loss of $13.9M, a divergence that may reflect working capital timing or non-cash items rather than a durable shift in earnings quality, and warrants further investigation over the next several quarters. Stock-based compensation of $5.5M to $9.3M per quarter is a meaningful add-back that partly explains the gap between net income and cash flow but does not account for the bulk of historical burn.

The magnitude of the improvement is substantial, but it is concentrated in a small number of quarters, and the 2026Q1 burn of -$15.6M and 2025Q4 burn of -$4.9M show that the trend is not yet linear. Capex remains negligible at well under 1% of revenue, so free cash flow is effectively a function of operating cash flow and the trajectory of commercial scaling. Investors should monitor whether the 2026Q3 result is repeatable before attributing it to a structural turn.

Large working capital outflows in 2024Q4 through 2025Q2, followed by inflows in 2025Q4 and 2026Q3, suggest that receivable collections or payables timing have affected cash results more than underlying operating economics in certain periods. Because the quarterly series is volatile, a single quarter's operating cash flow may overstate or understate the underlying run rate. The analysis would benefit from a trailing-twelve-month view before drawing firm conclusions about operating cash generation.